|Articles|October 1, 2021

Risk Factors Associated with Readmission after COVID-19 Hospitalization

Author(s)Nina Cosdon

After an initial hospitalization for COVID-19, some patients may have specific risk factors that increase their likelihood of readmittance.


Even after being cleared, hospitalized COVID-19 patients are not uncommonly readmitted.

In collaboration with Ascension St. John Hospital in Detroit, MI, investigators looked to identify risk factors for readmission after COVID-19 hospitalization.

They conducted a historical cohort study, including COVID-19 cases diagnosed via PCR testing from March 8-June 14, 2020. The study included 391 patients who survived initial hospitalization for COVID-19, and subsequently identified patients readmitted within 30 days of their release.

Investigators used the electronic medical record to collect demographic and clinical data, which were analyzed using Student’s t-test, the chi-squared test, and multivariable logistic regression.

The readmission rate was 13.3% (52 of 391 readmitted). The average time to readmission was 9.2 (± 7.9) days. The average age of the readmitted patients was 66.3 (± 18.6) years; the average age of patients not readmitted was 61 (± 16) years. 44.2% were male, and 78.8% were Black/African American. The most common symptom among the readmitted was shortness of breath (50%). The most frequent diagnosis for readmission was infectious process (57.7%).

Investigators also found that a need for ICU admission or mechanical ventilation during a patient’s initial hospitalization did not increase the risk of readmission. Readmitted patients had a higher prevalence of comorbidities, specifically heart failure and renal disease. Elevated alanine aminotransferase (AST) and/or low albumin level were also correlated with readmission. Of those readmitted, the mortality rate was 11.5%.

The multivariable analysis showed independent predictors of 30-day readmission, including higher Charlson score (p=0.004), higher creatinine on admission in the index hospitalization (p=0.009), and presence of rhabdomyolysis during the index hospitalization (p=0.039).

Of the patients readmitted, infectious etiologies were common. The independent predictors of hospital readmission within 30 days speak for themselves, but the investigators recommended further study into contributing risk factors.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.